Takara Bio Europe today announces the launch of Cellartis® MSC EV Wonder™, a defined, xeno-free medium engineered for the scalable production of extracellular vesicles (EVs) from human mesenchymal stem cells (MSCs).

MSC-derived EVs are increasingly recognized as next-generation, cell-free therapeutic candidates, offering regenerative and immunomodulatory benefits without the safety concerns associated with administering intact MSCs. As the field shifts from MSC-based approaches to MSC-EVs, researchers are seeking solutions that deliver both robust yields and reproducible quality at scale.

Cellartis MSC EV Wonder meets this need by enabling up to a nine-fold increase in EV production compared to conventional DMEM while maintaining critical attributes such as canonical CD marker expression, morphology, and RNA profile. The medium’s defined, phenol red–free formulation uses the same basal medium as the Cellartis MSC Xeno-Free Culture System, ensuring a seamless transition from MSC expansion to EV production.

“We developed Cellartis MSC EV Wonder around a chemically defined supplement that eliminates variability and preserves essential MSC-EV features, enabling reproducible results and a smooth transition to GMP manufacturing for clinical applications,” said Clemence Bonhomme, Scientist, Takara Bio Europe.

“Consistent, scalable production of high-quality MSC-EVs has been a bottleneck for the field,” said Tarik Hadi, PhD, Senior Market Strategy Manager at Takara Bio Europe. “With Cellartis MSC EV Wonder, we provide a defined solution that streamlines workflows, safeguards quality, and accelerates the path from discovery to translation.”

Cellartis MSC EV Wonder™ is now available. Researchers interested in testing the medium or obtaining further technical information are encouraged to contact us at infoEU@takarabio.com.

About Takara Bio

Takara Bio Europe, a subsidiary of Takara Bio Inc., is a leading manufacturer and supplier of molecular and cellular biology reagents and services. Their portfolio supports applications including NGS, cloning, viral transduction, protein expression and purification, gene editing, nucleic acid extraction and stem cell research.

Key products include SMART NGS kits for DNA- and RNA-seq, Cellartis cell culture reagents, high-performance qPCR and PCR reagents, and the innovative In-Fusion® cloning system. The portfolio also features the Shasta Single-Cell System for automated single-cell sequencing and the SmartChip platform for high-throughput qPCR. Takara Bio has recently expanded its capabilities to include spatial transcriptomics, complementing its existing expertise in NGS R&D, manufacturing, and automation solutions for NGS and qPCR applications

For more information, visit www.takarabio.com

About Takara Bio Inc.

Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP-grade reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin® reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.